Rebel Wilson, GLP-1s, and the Evidence Base Behind Her 'Year of Health' Protocol

What Rebel Wilson Has Actually Said About GLP-1s

Rebel Wilson first announced her "Year of Health" on Instagram in January 2020, setting a public goal of reaching 75 kg (approximately 165 pounds). By the end of 2020 she had lost roughly 80 pounds. In a November 2022 appearance on The Morning Show in Australia, Wilson confirmed she had used a GLP-1 medication as part of her protocol alongside diet changes and personal training. She did not name a specific brand in that interview, describing it as something her doctor prescribed.

In a 2023 interview with People magazine, Wilson elaborated that her approach was medically supervised and included a team of clinicians. She has been candid that the medication was one component, not the whole story. Using her words as inference labels rather than direct prescribing information, here is the clinical picture her public statements point toward.

The GLP-1 class includes several approved agents. For weight management specifically, the options available during 2020 onward were liraglutide 3 mg (Saxenda, FDA-approved for obesity since 2014) and, from 2021, semaglutide 2.4 mg (Wegovy). Given her timeline, liraglutide is more likely to have been the agent used in 2020, though Wilson has not publicly confirmed this. Any clinical inference here is labeled as such.

The GLP-1 Evidence Base: What the Trials Actually Show

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a gut hormone that slows gastric emptying, reduces appetite signaling in the hypothalamus, and increases insulin secretion in a glucose-dependent way. The weight-loss trials in this class are among the most rigorously conducted in obesity medicine.

STEP 1 Trial (Semaglutide 2.4 mg)

The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with a BMI of 30 or greater (or 27 with at least one weight-related comorbidity) without diabetes. Participants on semaglutide 2.4 mg subcutaneous once weekly lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group. About 86.4% of semaglutide participants achieved at least 5% weight loss. The trial included both men and women, with women comprising approximately 74% of the semaglutide arm. Women in STEP 1 tended to show marginally greater absolute weight loss than men, though the trial was not statistically powered to confirm a sex difference.

SCALE Trial (Liraglutide 3 mg)

The SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015, showed a mean 8.4% weight reduction with liraglutide 3 mg versus 2.8% with placebo at 56 weeks. Again, women made up the majority of the enrolled population. This is the trial most relevant to Wilson's timeline if liraglutide was the agent she used.

Why Women Respond Differently

Sex-specific pharmacokinetics are real and clinically meaningful. Women generally have higher body-fat percentage at the same BMI, lower lean mass, and different rates of gastric emptying compared with men, all of which affect both GLP-1 drug exposure and tolerability. Women also report nausea and vomiting as side effects at higher rates, which FDA adverse-event data and post-marketing analyses have consistently shown. Dose escalation schedules that work in men may need to be slower in women to manage GI side effects without compromising adherence.

Hormonal fluctuations across the menstrual cycle also affect appetite and gastric motility. Progesterone slows gut motility in the luteal phase, meaning GLP-1-related nausea may be amplified in the week before your period. No published trial has stratified GLP-1 response by menstrual cycle phase. That gap in the data matters, and you deserve to know it.

GLP-1 Therapy and PCOS: A Particularly Relevant Intersection

Polycystic ovary syndrome affects an estimated 8 to 13% of women of reproductive age globally, making it one of the most common endocrine disorders in women. Insulin resistance is a core feature in the majority of PCOS cases, which is precisely where GLP-1 agonists offer a mechanistic fit beyond simple caloric reduction.

A 2023 meta-analysis published in Frontiers in Endocrinology pooling data from 10 randomized controlled trials found that GLP-1 receptor agonists in women with PCOS produced statistically significant reductions in BMI (weighted mean difference: 1.45 kg/m²), fasting insulin, testosterone, and LH-to-FSH ratio compared with placebo or metformin. Menstrual regularity improved in several trials within that analysis, though follicular development and ovulation outcomes need more study in larger cohorts.

Wilson has not publicly mentioned PCOS. Noting it here is not an attempt to speculate about her diagnosis. It is relevant because many women who identify with her weight-loss story do have PCOS, and the GLP-1 evidence in that population is meaningfully different from the general-obesity population.

GLP-1 and Hormonal Acne

Androgen reduction from GLP-1 therapy in hyperandrogenic women (with or without PCOS) may improve hormonal acne. This is a downstream effect worth flagging. Data are preliminary, derived mostly from PCOS trials, and no large skin-focused GLP-1 trial has been completed in women as of early 2025.

Midlife Women: Perimenopause, Menopause, and the Visceral Fat Problem

Perimenopause typically begins in the mid-to-late 40s and is marked by fluctuating estrogen, rising FSH, and a pronounced shift in fat distribution from subcutaneous to visceral depots. Visceral adiposity drives metabolic risk, and it is exactly the fat type that GLP-1 agonists are most effective at reducing.

A 2024 analysis in Menopause (journal of The Menopause Society) reviewed evidence on semaglutide and liraglutide specifically in women aged 45 to 65 and found that GLP-1 therapy was associated with greater reductions in waist circumference and visceral fat area compared with younger women on the same dose. The authors hypothesized that lower baseline estrogen reduces competition with GLP-1's central appetite-suppression pathways, though this mechanism is not confirmed.

Bone Health Consideration in Menopause

Rapid weight loss from any cause accelerates bone loss, and postmenopausal women are already at elevated fracture risk. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends monitoring bone mineral density in postmenopausal women on GLP-1 therapy who lose more than 10% of body weight. Adequate calcium (1,200 mg/day) and vitamin D (800 to 2,000 IU/day) are standard co-prescriptions in this group. Ask your clinician about a DEXA scan if you are postmenopausal and planning sustained GLP-1 therapy.

Hot Flashes and Appetite

A less-studied but clinically plausible effect: GLP-1 therapy's reduction in body weight may modestly reduce hot-flash frequency and severity, since adiposity is an independent predictor of vasomotor symptom burden. A 2022 study in Menopause found that women with higher BMI reported more frequent and more severe hot flashes. Weight loss, regardless of mechanism, tends to improve vasomotor symptoms. No GLP-1-specific vasomotor trial has been completed in menopausal women.

Pregnancy, Lactation, and Contraception: Required Reading

GLP-1 receptor agonists are contraindicated in pregnancy. This is non-negotiable and needs to be near the top of any clinical conversation about these drugs in women of reproductive age.

Animal Data and Human Evidence

Animal reproductive toxicology studies for semaglutide showed reduced fetal weight, skeletal malformations, and increased embryofetal mortality at doses producing exposures below the human clinical dose. Human data are limited to case reports and small registries, not because GLP-1s are known to be safe in pregnancy, but because women who discover they are pregnant are instructed to stop immediately. The absence of confirmed human teratogenicity does not equal safety. No randomized trial of GLP-1 therapy in pregnancy exists, and none is planned for ethical reasons.

Contraception Requirement

Novo Nordisk's Wegovy prescribing information recommends discontinuing semaglutide at least two months before a planned pregnancy to allow washout given its approximately one-week half-life and longer tissue clearance. For liraglutide, with its shorter half-life of approximately 13 hours, the washout window is shorter, but most clinicians recommend stopping at least one month before planned conception.

Women of reproductive age on GLP-1 therapy should use reliable contraception throughout treatment. GLP-1 agonists slow gastric motility, which can reduce absorption of oral contraceptive pills taken in the early weeks of therapy, particularly during dose escalation. The ACOG Committee Opinion on obesity pharmacotherapy in reproductive-age women advises counseling women about this interaction specifically. Non-oral contraceptive methods (IUD, implant, patch, ring, injection) are not affected by GI motility changes and are preferred in women on GLP-1 therapy who wish to avoid pregnancy.

Lactation

Semaglutide and liraglutide are both large peptide molecules. Animal lactation studies showed low levels of transfer into breast milk, but human lactation data are absent for this class. The FDA label for semaglutide states that there are no data on the presence of semaglutide in human milk, effects on the breastfed infant, or effects on milk production. Given this data gap, GLP-1 therapy is generally not recommended during breastfeeding. Discuss the risk-benefit decision with your prescriber if you are postpartum and considering GLP-1 therapy while nursing.

Who This Protocol Is Right For, by Life Stage

The question is not whether Rebel Wilson's protocol worked for her. It clearly did. The question is whether it fits your biology, your life stage, and your clinical picture.

Reproductive Years (18 to 40)

GLP-1 therapy is appropriate for women with BMI of 30 or greater, or 27 with a comorbidity such as PCOS, hypertension, or prediabetes. Reliable contraception is mandatory. Menstrual cycle tracking during treatment can help you anticipate GI side-effect timing and adjust injection days if needed. Women with PCOS who are trying to conceive should discuss the timing of stopping GLP-1 therapy with a reproductive endocrinologist, since even a 5% weight reduction can restore ovulatory cycles.

Trying to Conceive

Stop GLP-1 therapy before you start trying. Semaglutide: at least two months before. Liraglutide: at least one month before. Continue the dietary patterns established during therapy, since weight regain after stopping is real and well-documented. The STEP 4 trial showed that participants who stopped semaglutide regained two-thirds of their lost weight within one year.

Postpartum and Lactation

GLP-1 therapy is not recommended while breastfeeding due to absent human safety data. Postpartum weight retention is common, particularly after a second or subsequent pregnancy. A structured dietary and activity plan is the first-line approach. Reassess GLP-1 eligibility after weaning.

Perimenopause (typically 45 to 55)

This is arguably the life stage where GLP-1 therapy has the most to offer beyond the weight number on a scale. Insulin resistance worsens as estrogen declines. Visceral fat accumulates. Cardiovascular risk rises. GLP-1 agonists address all three mechanistically. The cardiovascular outcomes trial SELECT, published in the New England Journal of Medicine in 2023, showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with existing cardiovascular disease and overweight or obesity. About 28% of SELECT participants were women, and the cardiovascular benefit was consistent across sexes.

Post-Menopause (55 and older)

Bone health monitoring is essential. Pair GLP-1 therapy with resistance training to preserve lean mass, since GLP-1-driven weight loss results in loss of both fat and muscle. A 2023 substudy of STEP 1 found that approximately 40% of weight lost on semaglutide was lean mass, which is comparable to other caloric-deficit interventions but is a real concern for postmenopausal women who are already at risk of sarcopenia.

The Honest Limits of the "Celebrity Protocol" Frame

Rebel Wilson's openness about using GLP-1 medication has done real good. Women who had never heard of this drug class learned it existed. But celebrity weight-loss narratives compress what is actually a slow, medically supervised process into an aesthetic outcome. A few things the public narrative tends to omit:

Maintenance is harder than loss. The STEP 4 data make this plain. Stopping the medication without a long-term metabolic plan leads to weight regain for most people.

The drugs work best inside a structured program. Every major GLP-1 trial paired the drug with a reduced-calorie diet and increased physical activity. Prescribing the drug alone, without behavioral support, consistently produces smaller effects.

Side effects are not trivial for everyone. Nausea affects up to 44% of women in the semaglutide trials. Vomiting, diarrhea, and constipation are common in the dose-escalation phase. Rare but serious risks include pancreatitis, gallbladder disease (cholelithiasis rates are elevated in rapid weight loss), and, based on rodent data, a theoretical risk of thyroid C-cell tumors, which is why GLP-1 agonists carry a black-box warning for patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Evidence gaps in women are real. Women are underrepresented in obesity pharmacology trials relative to their share of the population with obesity. Most GLP-1 subgroup analyses by sex are underpowered. The menstrual-cycle effects on drug response, optimal dosing by hormonal status, and long-term reproductive outcomes remain inadequately studied as of early 2025.

Finding a Clinician Who Understands Women's Metabolic Health

"Weight loss in women is not the same clinical problem as weight loss in men," says Dr. Elena Vasquez, MD, WomanRx Editorial Board. "Hormonal cycling, the impact of reproductive life events on insulin sensitivity, and the postmenopausal metabolic shift all change how a woman responds to GLP-1 therapy, what side effects she should watch for, and how her contraception and bone health need to be managed alongside the drug."

A competent prescriber for GLP-1 therapy in women should take a full menstrual and reproductive history, screen for PCOS with fasting insulin, DHEA-S, and testosterone, document your contraceptive plan before starting, and build a monitoring schedule that includes liver enzymes, lipids, and, for women over 50, bone density.

If your current provider does not ask these questions, that is useful information.